Shanghai Fochon Pharmaceutical Co., Ltd.

Fochon Pharmaceuticals, Ltd.

Chongqing Fochon Pharmaceutical Co., Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Fochon Pharmaceutical Co., Ltd.

Zhifang Chen

Weibo Wang

Xingdong Zhao

Haohan Tan

Xianlong Wang

Yanxin Liu

Jing Sun

Zuwen Zhou

Rui Tan

Lihua Jiang

Zhifu Li

Min Lin

Tongshuang Li

Ling Chen

Qihong Liu

Hongbin Liu

Yue Rong

Lijun Yang

Huajie Zhang

Weipeng Zhang

Qiang Tian

Chengxi He

Zongyao Zou

Kai Ran

Bin Liu

Li Linghu

Fanxin Zeng

Jiemin Fu

Quan Yuan

Hailong Shi

Bo Fang

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Apoptosis-inducing agents

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase

Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders. 

Compounds as BLC-2-selective apoptosis-inducing agents

Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.

Certain protein kinase inhibitors

Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors

Provided are certain CDK4/6 inhibitors with the structure of formula (I), pharmaceutical compositions thereof, and methods of use therefor. The compounds are of the class of pyrimidin-2 amine derivatives, useful for the treatment of hyper-proliferative diseases. 

Certain protein kinase inhibitor

Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof. 

Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Growing community of inventors

Chongqing, China

Zhifang Chen